PharmaCyte Biotech closes $7 million financing round

PharmaCyte Biotech Inc. (NASDAQ: PMCB) announced the completion of its previously disclosed $7 million financing round.

The biotechnology company reported having approximately $15.5 million in cash as of April 30, 2025, along with over $30 million in securities as documented in its most recent 10-K filing. The additional $7 million in proceeds strengthens the company's balance sheet.

"The successful completion of this financing is a welcome milestone as we continue on our growth trajectory," said Josh Silverman, Interim Chief Executive Officer of PharmaCyte. "We expect this additional capital, combined with our substantially reduced operational burn rate and our existing cash position and investments, to bring substantial value to our shareholders as we advance our initiatives and continue to evaluate opportunities that align with our long-term strategy."

PharmaCyte currently has approximately 6.8 million shares of common stock outstanding.

The Las Vegas-based company stated the financing provides financial flexibility to support ongoing business initiatives and strategic growth opportunities. Information is based on a company press release.

You May Also Be Interested In

• Ashland said to explore sale amid takeover interest - Bloomberg
• Rockstar Energy founder seeks CEO role at Celsius Holdings
• First Phosphate ADRs uplisted to Nasdaq Global Market as PHOS